Thomas co-founded NMD Pharma and has been CEO of the Company since its inception in 2015. During this time, NMD Pharma has transitioned from early a discovery-stage to clinical-stage company. He has led various financing rounds of the Company including raising one of the largest Series A investments in the sector in Europe in 2018.
The scientific basis of NMD Pharma – utilizing ClC-1 as a novel target for restoring muscle function in neuromuscular disease – comes from the academic work conducted at Aarhus University by Thomas and colleagues. Thomas obtained his PhD from Aarhus University and completed two years of post-doctoral work at Cambridge University. As a scientist, Thomas focused on cellular electrophysiology and ion channel biophysics, developing novel methods to understand the function and regulation of ClC-1 in health and disease. He has published more than 40 high-ranking papers including in Science and PNAS.